Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Allogene Therapeutics (ALLO) Stock Price & Analysis
1,081 Followers
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $6.41
Previous Close$2.77
Volume2.51M
Average Volume (3M)2.26M
Market Cap
$578.33M
Enterprise Value$217.98M
Total Cash (Recent Filing)$448.70M
Total Debt (Recent Filing)$88.35M
Price to Earnings (P/E)-1.5
Beta1.38
Next Earnings
Aug 07, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding170,853,379
10 Day Avg. Volume2,425,953
30 Day Avg. Volume2,259,896
Standard Deviation0.21
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.00
Price to Sales (P/S)4981.73
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.29K
Enterprise Value/Gross Profit2.29K
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
$12.23Price Target Upside341.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Allogene Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityAllogene's strong cash position, with an operational runway into 2026, underscores the company's financial stability and ability to fund future growth initiatives.
Safety ProfileCema-cel's differentiated safety profile may offer a competitive advantage over other therapies, potentially increasing its marketability and patient preference.
Strategic Market PositioningAllogene's pivot into the 1L setting for cema-cel represents a strategic move in a competitive market for CD19-targeted cell therapies, potentially positioning the company to capture market share.
Bears Say
Clinical TrialsYESCARTA is being evaluated in a trial that could challenge cema-cel's position if it manages to surpass the high efficacy benchmark of R-CHOP.
Company OutlookRisks include poorer than anticipated durability of effect, unexpected safety and immunogenicity concerns, unforeseen challenges in manufacturing, and long-term dilution risk.
Financial PerformanceAllogene recorded a net loss of $0.51 per share—wider than the estimated net loss.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $2.23 and its highest was $6.41 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 80 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.03.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.37.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 170,853,380 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went up 2.069%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 24M.
---
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.23 (341.52% Upside)
$12.23 (341.52% Upside)
Blogger Sentiment
Neutral
ALLO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 157.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $682.1 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.73%
12-Months-Change
Fundamentals
Return on Equity
-55.06%
Trailing 12-Months
Asset Growth
-21.49%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q1 2024
0:00 / 0:00
---
ALLO Stock 12 Month Forecast
Average Price Target
$12.23
▲(341.52% Upside)
Technical Analysis
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Editas Medicine
―
Beam Therapeutics
―
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-21.84%
reiterated a buy rating 6 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -21.84% per trade.
---